Automate Your Wheel Strategy on ERAS
With Tiblio's Option Bot, you can configure your own wheel strategy including ERAS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ERAS
- Rev/Share 0.0
- Book/Share 1.2263
- PB 8.6315
- Debt/Equity 0.1388
- CurrentRatio 10.446
- ROIC -0.3631
- MktCap 3276976331.0
- FreeCF/Share -0.347
- PFCF -33.2935
- PE -23.5168
- Debt/Assets 0.1149
- DivYield 0
- ROE -0.331
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 3
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | ERAS | Mizuho | -- | Outperform | -- | $16 | Jan. 27, 2026 |
| Initiation | ERAS | Piper Sandler | -- | Overweight | -- | $5 | Jan. 7, 2026 |
| Initiation | ERAS | Stifel | -- | Buy | -- | $4 | Oct. 16, 2025 |
| Downgrade | ERAS | BofA Securities | Buy | Underperform | -- | -- | Sept. 3, 2025 |
| Downgrade | ERAS | Morgan Stanley | Overweight | Equal Weight | -- | $2 | Aug. 18, 2025 |
| Initiation | ERAS | Raymond James | -- | Outperform | -- | $5 | March 26, 2025 |
News
Erasca Stock Surges 42% in a Week: Here's What You Should Know
Published: January 16, 2026 by: Zacks Investment Research
Sentiment: Positive
ERAS stock jumps 42% in a week after early phase I solid tumors study data for ERAS-0015 shows encouraging responses, favourable safety and faster-than-expected enrollment.
Read More
What's Going With Cancer Biotech Erasca Stock On Thursday?
Published: January 08, 2026 by: Benzinga
Sentiment: Negative
Erasca Inc. (NASDAQ: ERAS) shares on Wednesday jumped close to 60% to $6.12. On Thursday, the stock fell as low as $4.33.
Read More
Erasca to Present at the 8th Annual Evercore Healthcare Conference
Published: November 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the 8th Annual Evercore Healthcare Conference being held at the Loews Coral Gables Hotel in Coral Gables, FL. Management will participate in a fireside chat on Wednesday, December 3, 2025, at 10:25 am Eastern Time and will also participate in one-on-one investor meetings.
Read More
Erasca, Inc.: Carving A Different Niche In RAS Signaling
Published: April 25, 2025 by: Seeking Alpha
Sentiment: Positive
Erasca, Inc. focuses on developing novel targeted therapies for solid tumors, particularly through the RAS/MAP kinase pathway, with a promising yet early-stage pipeline. The company's lead program, naporafenib, shows preliminary efficacy in NRAS-mutant melanoma, with key phase 3 data expected in 2025. Financially stable with a cash runway into at least 2027, Erasca can advance its pipeline without immediate funding concerns, mitigating dilution risk.
Read More
About Erasca, Inc. (ERAS)
- IPO Date 2021-07-16
- Website https://www.erasca.com
- Industry Biotechnology
- CEO Jonathan E. Lim
- Employees 103